

AMPS2

ONLINE DAT Amphetamines II

Order information



REF		CONTENT		Analyzer(s) on which cobas c pack(s) can be used
08056781190	08056781500	ONLINE DAT Amphetamines II (850 tests)	System-ID 2016 001	cobas c 303 , cobas c 503 , cobas c 703

Materials required (but not provided):

Serum/plasma		
03304671190	Preciset DAT Plus I CAL 6 (1 x 5 mL)	Code 20436
07978766190	Serum DAT Control Low (ACQ Partner Channel*)	
07978740190	Serum DAT Control High (ACQ Partner Channel*)	
08063494190	NaCl Diluent 9 % (123 mL)	System-ID 29006 001

*Roche does not hold the product registration for Partner Channels. The legal manufacturer indicated on the kit is solely responsible for all of the design, legal, and regulatory aspects of the product.

Urine		
03304671190	Preciset DAT Plus I CAL 1-6 (6 x 5 mL)	Codes 20431-20436
03304680190	Preciset DAT Plus II CAL 1-6 (6 x 5 mL)	Codes 20437-20442
03304698190	C.f.a.s. DAT Qualitative Plus (6 x 5 mL)	Code 20698
04590856190	C.f.a.s. DAT Qualitative Plus Clinical (3 x 5 mL)	Code 20699
03312968190	Control Set DAT II (for 300 ng/mL assay) PreciPos DAT Set II (2 x 10 mL) PreciNeg DAT Set II (2 x 10 mL)	
03312950190	Control Set DAT I (for 500 ng/mL assay) PreciPos DAT Set I (2 x 10 mL) PreciNeg DAT Set I (2 x 10 mL)	
04500873190	Control Set DAT Clinical (for 500 ng/mL assay) PreciPos DAT Clinical (2 x 10 mL) PreciNeg DAT Clinical (2 x 10 mL)	
03312976190	Control Set DAT III (for 1000 ng/mL assay) PreciPos DAT Set III (2 x 10 mL) PreciNeg DAT Set III (2 x 10 mL)	

English

System information

AMQ3S: ACN 20167 (Serum/plasma): for qualitative assay, 300 ng/mL

AM3Q2: ACN 20161 (Urine): for qualitative assay, 300 ng/mL

AM5Q2: ACN 20162 (Urine): for qualitative assay, 500 ng/mL

AM1Q2: ACN 20163 (Urine): for qualitative assay, 1000 ng/mL

AM3S2: ACN 20164 (Urine): for semiquantitative assay, 300 ng/mL

AM5S2: ACN 20165 (Urine): for semiquantitative assay, 500 ng/mL

AM1S2: ACN 20166 (Urine): for semiquantitative assay, 1000 ng/mL

AM5QC: ACN 20160 (Urine): for qualitative assay, 500 ng/mL; using C.f.a.s. DAT Qualitative Plus Clinical

AM5-QP: ACN 20168 (Urine): for qualitative assay, 500 ng/mL; using C.f.a.s. DAT Qualitative Plus

Intended use

Application in urine

Amphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of amphetamines and methamphetamines in human urine on **cobas c** systems at cutoff concentrations of 300 ng/mL, 500 ng/mL, and 1000 ng/mL when calibrated with *d*-methamphetamine. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas

chromatography/mass spectrometry (GC-MS). Amphetamines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC-MS is the preferred confirmatory method.¹ Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

Application in serum and plasma*

*not available in all countries

Amphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative detection of amphetamines and methamphetamines in human serum and plasma on **cobas c** systems. For serum/plasma the cutoff concentration is 300 ng/mL when calibrated with *d*-methamphetamine. Amphetamines II provides only a preliminary test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC-MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC-MS/MS) is the preferred confirmatory method.¹ Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

Summary

Detection of amphetamines with this assay in human serum, plasma and urine is used for presumptive testing of exposure to amphetamines in individuals with suspected exposure.

The amphetamines are known as the sympathomimetic amines as they mimic the effects of stimulation of the sympathetic nervous system. These small molecules structurally resemble the body's own catecholamines. A

wide variety has been created via substitutions anywhere on the structure. The amphetamines are potent central nervous stimulants. As such they can increase wakefulness, physical activity, and decrease appetite. The amphetamines have some limited indications and approval for use in ADHD, narcolepsy, and obesity. However, because these CNS stimulants convey a sense of self-confidence, well being, and euphoria, they are highly addictive, widely abused, and consequently controlled substances.^{2,3} Abuse can lead to medical, psychological, and social consequences. Adverse health effects include memory loss, aggression, psychotic behavior, heart damage, malnutrition, and severe dental problems.⁴ Amphetamine is a metabolite of a number of other drugs including methamphetamine. Normally about 30-40 % of the ingested amphetamine is excreted unchanged in the 24 hour urine at normal urine pH, but excretion can increase with an acidic pH (up to 78 % / 24 h, 68 % unchanged) and decrease with an alkaline pH (45 % / 24 h, 2 % unchanged).⁵

In pain management patients, and individuals under rehabilitation programs, amphetamine testing is recommended to identify its illicit use and to monitor adherence to addiction treatment and abstinence.^{6,7} In the context of drug screening, samples that test negative on initial screening tests can be reported as negative and disposed of as planned. Otherwise, depending on the situation, presence of the drugs indicated by a positive screening result may need to be confirmed using a suitable confirmatory technique (e.g., GC-MS or LC-MS).^{5,7,8,9} Structural similarities of many over-the-counter products and several prescription medications may also be detected by the assay (for details see "Analytical specificity" section).^{8,10}

Amphetamines II is calibrated with d-methamphetamine and therefore the sensitivity towards amphetamines is different than d-methamphetamine, as indicated in the "Analytical specificity" section.

Test principle

The assay is based on the kinetic interaction of microparticles in a solution (KIMS)^{11,12} as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases.

When a sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.¹³

Reagents - working solutions

- R1** Conjugated amphetamine and methamphetamine derivatives; buffer; bovine serum albumin; 0.09 % sodium azide
- R2** Microparticles attached to amphetamine and methamphetamine antibodies (mouse monoclonal); buffer; bovine serum albumin; 0.09 % sodium azide

R1 is in position B and R2 is in position C.

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

Reagent handling

Ready for use

Carefully invert reagent container several times prior to use to ensure that the reagent components are mixed.

Storage and stability

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label

On-board in use and refrigerated on the analyzer: 26 weeks

Do not freeze.

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum: Serum tubes with and without separating gel.

Plasma: K₂- or K₃-EDTA, lithium heparin plasma.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Stability in serum/plasma:

5 days capped at 15-25 °C

14 days capped at 2-8 °C

6 months capped at -20 °C (± 5 °C)

Specimens can be repeatedly frozen and thawed up to 3 times.

Invert thawed specimens several times prior to testing.

Urine: Collect urine samples in clean glass or plastic containers. Fresh urine specimens do not require any special handling or pretreatment, but an effort should be made to keep pipetted samples free of gross debris.

Samples should be within the normal physiological pH range of 5-8. No additives or preservatives are required. It is recommended that urine specimens be stored at 2-8 °C and tested within 5 days of collection.¹⁴

For prolonged storage, freezing of the sample is recommended.¹⁴

Freeze only once.

Adulteration or dilution of the sample can cause erroneous results. If adulteration is suspected, another sample should be collected. Specimen validity testing is required for specimens collected under the *Mandatory Guidelines for Federal Workplace Drug Testing Programs*.¹⁵

Centrifuge highly turbid specimens or samples containing precipitates before performing the assay.

See the limitations and interferences section for details about possible sample interferences.

CAUTION: Specimen dilutions should only be used to interpret results of Calc.? and Samp.? alarms, or when estimating concentration in preparation for GC-MS or LC-MS/MS. Dilution results are not intended for patient values. Dilution procedures, when used, should be validated.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

General laboratory equipment

See "Order information" section

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for serum/plasma

Test definition - 300 ng/mL cutoff assay

	Qualitative	
Reporting time	10 min	
Wavelength (sub/main)	- /600 nm	
Reagent pipetting		Diluent (H ₂ O)
R1	62 µL	-

R2	27 µL	-	
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (H₂O)</i>
Normal	4.1 µL	-	-
Decreased	4.1 µL	-	-
Increased	4.1 µL	-	-

Application for urine**Test definition - 300 ng/mL cutoff assay**

	Semiquantitative	Qualitative	
Reporting time	10 min	10 min	
Wavelength (sub/main)	-/600 nm	-/600 nm	
Reagent pipetting		Diluent (H ₂ O)	
R1	62 µL	-	
R2	27 µL	-	
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	4.1 µL	-	-
Decreased	4.1 µL	-	-
Increased	4.1 µL	-	-

Test definition - 500 ng/mL cutoff assay

	Semiquantitative	Qualitative	
Reporting time	10 min	10 min	
Wavelength (sub/main)	-/600 nm	-/600 nm	
Reagent pipetting		Diluent (H ₂ O)	
R1	62 µL	-	
R2	27 µL	-	
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	3.4 µL	-	-
Decreased	3.4 µL	-	-
Increased	3.4 µL	-	-

Test definition - 1000 ng/mL cutoff assay

	Semiquantitative	Qualitative	
Reporting time	10 min	10 min	
Wavelength (sub/main)	-/600 nm	-/600 nm	
Reagent pipetting		Diluent (H ₂ O)	
R1	62 µL	-	
R2	27 µL	-	
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	2.7 µL	-	-
Decreased	2.7 µL	-	-
Increased	2.7 µL	-	-

For further information about the assay test definitions refer to the application parameters setting screen of the corresponding analyzer and assay.

Calibration

Serum/plasma

Qualitative application

Calibrator	300 ng/mL cutoff assay
	S1: Preciset DAT Plus I, CAL 6, 5000 ng/mL with automatic pre-dilution
Cutoff calibrator	A value of "0" is encoded in the e-barcode in order to ensure flagging of positive samples with >Test and negative absorbance values for negative samples.
Calibration K factor	The K factor of -1000 is predefined in the application settings.
Calibration mode	Linear
Calibration frequency	Full calibration
	- after reagent lot change
	- every 6 weeks on-board
	- as required following quality control procedures

Urine**Semiquantitative applications**

Calibrators	300 ng/mL cutoff assay
	S1-6: Preciset DAT Plus II, CAL 1-6, 0, 150, 300, 600, 1000, 2000 ng/mL
	500 and 1000 ng/mL cutoff assays
	S1-6: Preciset DAT Plus I, CAL 1-6, 0, 250, 500, 1000, 3000, 5000 ng/mL
Calibration mode	Non-linear
Calibration frequency	Full calibration
	- after reagent lot change
	- every 6 weeks on-board
	- as required following quality control procedures

Qualitative applications

Calibrators	300 ng/mL cutoff assay
	S1: Preciset DAT Plus II, CAL 3, 300 ng/mL
	500 ng/mL cutoff assay
	S1: Preciset DAT Plus I, CAL 3 or C.f.a.s. DAT Qualitative Plus
	S1: C.f.a.s. DAT Qualitative Plus Clinical, 500 ng/mL
	1000 ng/mL cutoff assay
	S1: Preciset DAT Plus I, CAL 4, 1000 ng/mL
Cutoff calibrator	A value of "0" is encoded in the e-barcode in order to ensure flagging of positive samples with >Test and negative absorbance values for negative samples.
Calibration K factor	The K factor of -1000 is predefined in the application settings.
Calibration mode	Linear
Calibration frequency	Full calibration
	- after reagent lot change
	- every 6 weeks on-board
	- as required following quality control procedures

The drug concentrations of the calibrators have been verified by GC-MS.

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against a primary reference method (GC-MS).

Quality control

For quality control, use control materials as listed in the "Order information" section. In addition, other suitable control material can be used.

Drug concentrations of the Serum DAT controls, Control Set DAT I, II, III and Clinical have been verified by LC-MS/MS.

The control intervals and limits should be adapted to each laboratory's individual requirements. It is recommended to perform quality control always after lot calibration and subsequently at least every 26 weeks.

Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Results

For the qualitative assay, the cutoff calibrator is used as a reference in distinguishing between preliminary positive and negative samples. Samples producing a positive or "0" absorbance value are considered preliminary positive. Preliminary positive samples are flagged with >Test. Samples producing a negative absorbance value are considered negative. Negative samples are preceded by a minus sign. Results of this assay distinguish preliminary positive (≥ 300 ng/mL, ≥ 500 ng/mL or ≥ 1000 ng/mL depending on the cutoff) from negative samples only. The amount of drug detected in a preliminary positive sample cannot be estimated.

For the semiquantitative applications **cobas c** systems automatically calculate the drug or metabolite concentration of each sample in the unit ng/mL. Results equal to or greater than the respective cutoff value are considered preliminary positive. Concentration values below the respective cutoff indicate a negative result.

The semiquantitation of preliminary positive results should only be used by laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GC-MS. It also permits the laboratory to establish quality control procedures and assess control performance.

Results of this assay yield only approximate cumulative concentrations of the drug and its metabolites (see "Analytical specificity" section).

NOTE: If a result of Calc.? or Samp.? alarm is obtained, review the Reaction Monitor data for the sample and compare with the Reaction Monitor data for the highest calibrator. The most likely cause is a high concentration of the analyte in the sample, in which case the absorbance value for the sample will be less than that of the highest calibrator. Make an appropriate dilution of the sample using the 0 ng/mL calibrator and rerun the sample. A normal drug-free urine may be substituted for the 0 ng/mL calibrator if the urine and procedure have been validated by the laboratory. To ensure that the sample was not over-diluted, the diluted result, prior to multiplying by the dilution factor, must be at least half the analyte cutoff value. If the diluted result falls below half the analyte cutoff value, repeat the sample with a smaller dilution. A dilution that produces a result closest to the analyte cutoff is the most accurate estimation. To estimate the preliminary positive sample's concentration, multiply the result by the appropriate dilution factor. Dilutions should only be used to interpret results of Calc.? or Samp.? alarms, or when estimating concentration in preparation for GC-MS or LC-MS/MS.

Use caution when reporting results as there are various factors that influence a urine test result, such as fluid intake and other biological factors.

As with any sensitive test for drugs of abuse on automated clinical chemistry analyzers, the possibility exists for analyte carry-over from a sample with an extremely high concentration to a normal (negative) sample which immediately follows it.

Preliminary positive results should be confirmed by another method.

Limitations - interference

See the "Specific performance data" section of this document for information on substances tested with this assay. There is the possibility that other substances and/or factors may interfere with the test and cause erroneous results (e.g., technical or procedural errors).

A preliminary positive result with this assay indicates the presence of amphetamines/methamphetamines and/or their metabolites in serum or urine. It does not measure the level of intoxication.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹⁶

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Serum/plasma

Criterion: No cross-over at initial values of samples of 150 ng/mL and 450 ng/mL (control levels).

Icterus:¹⁷ No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 μ mol/L or 60 mg/dL).

Hemolysis:¹⁷ No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 622 μ mol/L or 1000 mg/dL).

Lipemia (native lipaemic samples):¹⁷ No significant interference up to an L index of 100. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Rheumatoid factors: No significant interference from rheumatoid factors up to a concentration of 100 IU/mL.

Immunoglobulins: No significant interference from immunoglobulins up to a concentration of 16 g/L (simulated by human immunoglobulin A), up to a concentration of 70 g/L (simulated by human immunoglobulin G) and up to a concentration of 10 g/L (simulated by human immunoglobulin M).

Albumin: No significant interference from human serum albumin up to a concentration of 70 g/L.

As with any assay employing mouse antibodies, the possibility exists for interference by human anti-mouse antibodies (HAMA) in the sample, which could cause falsely lowered results.

Urine

Interfering substances were added to urine containing *d*-methamphetamine (MAMP) at -25 % and +25 % of the cutoff level at the concentration listed below. The same substances were additionally added to urine containing *d*-amphetamine (AMP) at -25 % and +25 % of the cutoff level at the concentration listed below. All samples were tested and the following results were obtained on a Roche/Hitachi 917 analyzer. The value in the table indicates the level at which no interference was found for samples containing either *d*-methamphetamine or *d*-amphetamine.

Qualitative	Compound	Cmpd. conc.	300 ng/mL cutoff		500 ng/mL cutoff		1000 ng/mL cutoff	
			Neg. level	Pos. level	Neg. level	Pos. level	Neg. level	Pos. level
	Acetone	7.9 mg/mL	NEG	POS	NEG	POS	NEG	POS
	Ascorbic acid	10 mg/mL	NEG	POS	NEG	POS	NEG	POS
	Conjugated bilirubin	0.1 mg/mL	NEG	POS	NEG	POS	NEG	POS
	Creatinine	2.75 mg/mL	NEG	POS	NEG	POS	NEG	POS
	Ethanol	7.9 mg/mL	NEG	POS	NEG	POS	NEG	POS
	Glucose	20 mg/mL	NEG	POS	NEG	POS	NEG	POS
	Hemoglobin	1 mg/mL	NEG	POS	NEG	POS	NEG	POS
	Human serum albumin	5 mg/mL	NEG	POS	NEG	POS	NEG	POS
	Magnesium chloride*	2 mg/mL	NEG	POS	NEG	POS	NEG	POS

Qualitative		300 ng/mL cutoff		500 ng/mL cutoff		1000 ng/mL cutoff	
Oxalic acid	2 mg/mL	NEG	POS	NEG	POS	NEG	POS
Sodium chloride	14.6 mg/mL	NEG	POS	NEG	POS	NEG	POS
Urea	50 mg/mL	NEG	POS	NEG	POS	NEG	POS

The same experiment was performed in the semiquantitative mode for each cutoff. All negative and positive controls recovered properly in the presence of the interfering substance.

A protocol was executed in which samples containing MAMP at control levels ($\pm 25\%$ of cutoff) with specific gravities ranging from 1.001 to 1.020 were tested. As with the other interferences, there were no control cross-overs on any of the 3 assay cutoffs at either extreme specific gravity level.

An additional protocol was executed in which samples containing MAMP at control levels ($\pm 25\%$ of cutoff) with pH ranging from 4.5 to 8.0 were tested.

As with the other interferences, there were no control cross-overs on any of the assay cutoffs at either extreme pH level.

*Results were obtained on a cobas c 501 analyzer.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹⁶

ACTION REQUIRED

When running Amphetamines II and Tina-quant Hemoglobin A1c II assays on the same **cobas c 503** analyzer, avoid processing Amphetamines II as the first test from standby status. If no other testing is pending, a dummy test sample should be processed to prevent the Amphetamines II from being the first test from standby. Order a dummy test for any R1 assay other than HbA1c II.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on **cobas c** systems. All special wash programming necessary for avoiding carry-over is available via the **cobas** link. The latest version of the carry-over evasion list can be found with the NaOHD/SMS/SCCS Method Sheet. For further instructions, refer to the operator's manual.

Expected values

Serum/plasma/urine

No drug should be present in individuals that have not ingested amphetamine or methamphetamine.

Serum/plasma

Qualitative assay

Results of this assay distinguish preliminary positive (≥ 300 ng/mL) from negative samples only. The amount of drug detected in a preliminary positive sample cannot be estimated.

Specific performance data

Representative performance data on the analyzers are given below. These data represent the performance of the analytical procedure itself.

Results obtained in individual laboratories may differ due to heterogenous sample materials, aging of analyzer components and mixture of reagents running on the analyzer.

Precision

Serum/plasma

Precision was determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP05-A3 requirements with repeatability ($n = 84$) and intermediate precision (2 aliquots per run, 2 runs per day, 21 days). Results for repeatability and intermediate precision were obtained on the **cobas c 503** analyzer.

Qualitative precision - 300 ng/mL cutoff

Cutoff (300)	Number tested	Correct results	Confidence level
Serum -75 %	84	84	> 95 % negative reading

ACQ-L	84	84	> 95 % negative reading
Cutoff serum	84	n.a.**	n.a.**
ACQ-H	84	84	> 95 % positive reading
Serum +75 %	84	84	> 95 % positive reading

**n.a. = not applicable

The data obtained on **cobas c 503** analyzer(s) are representative for **cobas c 303** analyzer(s) and **cobas c 703** analyzer(s).

Urine

Precision was determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP05-A3 requirements with repeatability ($n = 84$) and intermediate precision (2 aliquots per run, 2 runs per day, 21 days). Results for repeatability and intermediate precision were obtained on the **cobas c 503** analyzer.

Semiquantitative precision - 300 ng/mL cutoff

Repeatability	Mean ng/mL	SD ng/mL	CV %
Urine -50 %	143	5.76	4.0
DAT2N	224	6.47	2.9
Cutoff urine	291	7.87	2.7
DAT2P	377	11.2	3.0
Urine +50 %	461	9.10	2.0

Intermediate precision	Mean ng/mL	SD ng/mL	CV %
Urine -50 %	143	7.16	5.0
DAT2N	224	8.41	3.8
Cutoff urine	291	9.74	3.3
DAT2P	377	14.4	3.8
Urine +50 %	461	13.9	3.0

Qualitative precision - 300 ng/mL cutoff

Cutoff (300)	Number tested	Correct results	Confidence level
Urine -50 %	84	84	> 95 % negative reading
DAT2N	84	84	> 95 % negative reading
Cutoff urine	84	n.a.*	n.a.*
DAT2P	84	84	> 95 % positive reading
Urine +50 %	84	84	> 95 % positive reading

*n.a. = not applicable

Semiquantitative precision - 500 ng/mL cutoff

Repeatability	Mean ng/mL	SD ng/mL	CV %
Urine -50 %	282	8.31	2.9
DAT1N	364	12.5	3.4
DATCN	360	13.7	3.8
Cutoff urine	524	11.8	2.2
DAT1P	619	15.1	2.4
DATCP	611	16.5	2.7
Urine +50 %	717	23.3	3.2

Intermediate precision	Mean ng/mL	SD ng/mL	CV %
Urine -50 %	282	9.03	3.2

DAT1N	364	13.1	3.6
DATCN	360	15.3	4.3
Cutoff urine	524	14.8	2.8
DAT1P	619	15.7	2.5
DATCP	611	18.4	3.0
Urine +50 %	717	25.0	3.5

Qualitative precision - 500 ng/mL cutoff

Cutoff (500)	Number tested	Correct results	Confidence level
Urine -50 %	84	84	> 95 % negative reading
DAT1N	84	84	> 95 % negative reading
DATCN	84	84	> 95 % negative reading
Cutoff urine	84	n.a.*	n.a.*
DAT1P	84	84	> 95 % positive reading
DATCP	84	84	> 95 % positive reading
Urine +50 %	84	84	> 95 % positive reading

*n.a. = not applicable

Semiquantitative precision - 1000 ng/mL cutoff

Repeatability	Mean	SD	CV
	ng/mL	ng/mL	%
Urine -50 %	502	14.6	2.9
DAT3N	737	16.9	2.3
Cutoff urine	988	22.0	2.2
DAT3P	1219	25.7	2.1
Urine +50 %	1557	53.3	3.4

Intermediate precision	Mean	SD	CV
	ng/mL	ng/mL	%
Urine -50 %	502	16.3	3.3
DAT3N	737	19.5	2.7
Cutoff urine	988	27.9	2.8
DAT3P	1219	35.0	2.9
Urine +50 %	1557	56.4	3.6

Qualitative precision - 1000 ng/mL cutoff

Cutoff (1000)	Number tested	Correct results	Confidence level
Urine -50 %	84	84	> 95 % negative reading
DAT3N	84	84	> 95 % negative reading
Cutoff urine	84	n.a.*	n.a.*
DAT3P	84	84	> 95 % positive reading
Urine +50 %	84	84	> 95 % positive reading

*n.a. = not applicable

The data obtained on **cobas c 503** analyzer(s) are representative for **cobas c 303** analyzer(s) and **cobas c 703** analyzer(s).

Accuracy

Serum/plasma

73 serum samples obtained from a clinical laboratory, where they screened negative in a drug test panel, were evaluated with the Amphetamines II assay. 100 % of these normal serum samples were negative relative to the 300 ng/mL cutoff.

30 samples obtained from a clinical laboratory, where they were screened preliminary positive with a commercially available immunoassay, were evaluated with the Amphetamines II assay. 100 % of these serum samples were positive relative to the 300 ng/mL cutoff.

In addition, 21 samples were found in a concentration of 100-150 % of the cutoff concentration; and 37 samples were found in a concentration of 50-100 % of the cutoff concentration. The following results were obtained with the Amphetamines II assay on the **cobas c 501** analyzer relative to the LC-MS/MS values.

Note: Several LC-MS/MS methods do not distinguish between the *d*- and *l*-enantiomers of amphetamines, whereas the Amphetamines II assay does. AMPS II detects only the *d*-enantiomere, which is the active CNS stimulant (see section "Analytical specificity"). For distribution of *d*- and *l*-enantiomers see reference 10.¹⁸

		n = 161			
		LC-MS/MS			
		neg	neg near cutoff	pos near cutoff	pos
cobas c 501 analyzer	neg	73	26	6	0
	pos	0	11	15	30

Additional clinical samples were evaluated with this assay on a **cobas c 503** analyzer and a **cobas c 501** analyzer. 105 serum samples screened negative in a drug test panel, were evaluated with the Amphetamines II assay. 100 % of these normal serum samples were negative relative to the **cobas c 503** analyzer. 55 serum samples screened positive in a drug test panel, were evaluated with the Amphetamines II assay. 100 % of the serum samples were positive on both the **cobas c 501** analyzer and the **cobas c 503** analyzer.

Amphetamines II correlation (cutoff = 300 ng/mL)			
		cobas c 501 analyzer	
		+	-
cobas c 503 analyzer	+	55	0
	-	0	105

Additional clinical samples were evaluated with this assay on a **cobas c 303** analyzer and a **cobas c 501** analyzer. 93 serum samples screened negative in a drug test panel, were evaluated with the Amphetamines II assay. 100 % of these normal serum samples were negative relative to the **cobas c 303** analyzer. 51 serum samples screened positive in a drug test panel, were evaluated with the Amphetamines II assay. 100 % of the serum samples were positive on both the **cobas c 501** analyzer and the **cobas c 303** analyzer.

Amphetamines II correlation (cutoff = 300 ng/mL)			
		cobas c 501 analyzer	
		+	-
cobas c 303 analyzer	+	51	0
	-	0	93

Additional clinical samples were evaluated with this assay on a **cobas c 703** analyzer and a **cobas c 503** analyzer. 99 serum samples screened negative in a drug test panel, were evaluated with the Amphetamines II assay. 100 % of these normal serum samples were negative relative to the **cobas c 703** analyzer. 53 serum samples screened positive in a drug test panel, were evaluated with the Amphetamines II assay. 100 % of the serum samples were positive on both the **cobas c 503** analyzer and the **cobas c 703** analyzer.

Amphetamines II correlation (cutoff = 300 ng/mL)			
		cobas c 503 analyzer	
		+	-
cobas c 703 analyzer	+	53	0
	-	0	99

Urine

An initial study was conducted in which samples were selected based upon screening with a commercially available enzyme immunoassay. The study resulted in 190 unaltered clinical samples (114 negative and 76 preliminary positive) for the 300 ng/mL cutoff, 189 unaltered clinical samples

(114 negative and 75 preliminary positive) for the 500 ng/mL cutoff, and 189 unaltered clinical samples (115 negative and 74 preliminary positive) for the 1000 ng/mL cutoff. 100 % of the samples that screened preliminary positive were confirmed positive with GC-MS. For the 300 ng/mL and 500 ng/mL cutoffs, 47 of the samples that screened negative were confirmed negative with GC-MS. For the 1000 ng/mL cutoff, 48 of the samples that screened negative were confirmed negative with GC-MS. The following results were obtained with the Amphetamines II assay on a **cobas c 501** analyzer relative to the total GC-MS values:

Amphetamines II qualitative assay results (total GC-MS)

Roche ONLINE DAT AMPII assay	Low neg	Near cutoff negative by GC-MS (between -50 % and cutoff)	Near cutoff positive by GC-MS (between cutoff and +50 %)	High positive by GC-MS (greater than +50 %)	Percent agreement with GC-MS (total)
300 ng/mL cutoff					
Positive	2	1	7	69	100 %
Negative	108	3	0	0	97.4 %
500 ng/mL cutoff					
Positive	0	0	6	69	100 %
Negative	110	4	0	0	100 %
1000 ng/mL cutoff					
Positive	0	0	7	66	98.6 %
Negative	110	5	0	1	100 %

Amphetamines II semiquantitative assay results (total GC-MS)

Roche ONLINE DAT AMPII assay	Low neg	Near cutoff negative by GC-MS (between -50 % and cutoff)	Near cutoff positive by GC-MS (between cutoff and +50 %)	High positive by GC-MS (greater than +50 %)	Percent agreement with GC-MS (total)
300 ng/mL cutoff					
Positive	1	0	7	69	100 %
Negative	109	4	0	0	99.1 %
500 ng/mL cutoff					
Positive	0	0	6	69	100 %
Negative	110	4	0	0	100 %
1000 ng/mL cutoff					
Positive	0	0	7	66	98.6 %
Negative	110	5	0	1	100 %

Accuracy samples were categorized based upon the total GC-MS concentration. The table below identifies those samples with a total GC-MS concentration that is discrepant from the results obtained with ONLINE DAT Amphetamines II assay on a **cobas c 501** analyzer. The expected results column identifies the result expected with the Amphetamines II assay based upon the cross reactivity of Amphetamines II towards both *d*-methamphetamine (MAMP) and *d*-amphetamine (AMP) values relative to the cutoff.

GC-MS summary of discrepant results (total GC-MS)

Cutoff value (ng/mL)	Roche ONLINE DAT AMPII OBSERVED result	Roche ONLINE DAT AMPII EXPECTED result	GC-MS (ng/mL)	Drug / Metabolite
300 (Q) ^{a)}	Positive	Negative	174	MAMP

300 (SQ, Q)	Positive	Negative	58710 278	Pseudoephedrine Ephedrine
300 (Q)	Positive	Negative	76730 124	Pseudoephedrine Ephedrine
1000 (SQ, Q) ^{b)}	Negative	Positive	2834	AMP

a) The cause of the discrepancy could not be determined.

b) After accuracy testing was completed, the sample volume was inadequate to undertake a root cause analysis of the discrepant sample. The cause of the discrepancy could not be determined.

Two additional studies were conducted in which samples were selected based on GC-MS values for either *d*-methamphetamine or *d*-amphetamine. A total of 80 unaltered clinical samples (40 negative and 40 positive) were evaluated by the Amphetamines II assay and by GC-MS. Approximately 10 % of the study samples were distributed between plus and minus 50 % of the claimed cutoff concentration. The following results were obtained with the Amphetamines II assay on a **cobas c 501** analyzer relative to the GC-MS values for either *d*-methamphetamine (MAMP) and *d*-amphetamine (AMP).

Amphetamines II qualitative assay results (MAMP)

Roche ONLINE DAT AMPII assay	Low neg	Near cutoff negative by GC-MS (between -50 % and cutoff)	Near cutoff positive by GC-MS (between cutoff and +50 %)	High positive by GC-MS (greater than +50 %)	Percent agreement with GC-MS (total)
300 ng/mL cutoff					
Positive	0	4	4	36	100 %
Negative	36	0	0	0	90 %
500 ng/mL cutoff					
Positive	0	3	4	36	100 %
Negative	36	1	0	0	92.5 %
1000 ng/mL cutoff					
Positive	0	4	4	36	100 %
Negative	36	0	0	0	90 %

Amphetamines II semiquantitative assay results (MAMP)

Roche ONLINE DAT AMPII assay	Low neg	Near cutoff negative by GC-MS (between -50 % and cutoff)	Near cutoff positive by GC-MS (between cutoff and +50 %)	High positive by GC-MS (greater than +50 %)	Percent agreement with GC-MS (total)
300 ng/mL cutoff					
Positive	0	4	4	36	100 %
Negative	36	0	0	0	90 %
500 ng/mL cutoff					
Positive	0	3	4	36	100 %
Negative	36	1	0	0	92.5 %
1000 ng/mL cutoff					
Positive	0	4	4	36	100 %
Negative	36	0	0	0	90 %

Accuracy samples were categorized based upon the *d*-methamphetamine GC-MS concentration only. The table below identifies those samples with a *d*-methamphetamine concentration below the cutoff, in which the observed result on a **cobas c 501** analyzer was positive. The expected results column identifies the result expected with the Amphetamines II assay based upon the *d*-methamphetamine (MAMP) value relative to the cutoff.

GC-MS summary of discrepant results (MAMP)

Cutoff value (ng/mL)	Roche ONLINE DAT AMPII OBSERVED result	Roche ONLINE DAT AMPII EXPECTED result	GC-MS (ng/mL)	Drug / Metabolite
300 (SQ, Q)	Positive	Positive	173 181	MAMP AMP
300 (SQ, Q)	Positive	Positive	278 101	MAMP AMP
300 (SQ, Q)	Positive	Positive	220 171	AMP MAMP
300 (SQ, Q)	Positive	Positive	291 145	MAMP AMP
500 (SQ, Q)	Positive	Positive	488 466	MAMP AMP
500 (SQ, Q)	Positive	Positive	325 171	MAMP AMP
500 (SQ, Q)	Positive	Positive	291 145	MAMP AMP
500 (SQ, Q)	Positive	Positive	472 650	MAMP AMP
1000 (SQ, Q)	Positive	Positive	706 443	MAMP AMP
1000 (SQ, Q)	Positive	Positive	540 693	MAMP AMP
1000 (SQ, Q)	Positive	Positive	769 395	MAMP AMP
1000 (SQ, Q)	Positive	Positive	572 432	MAMP AMP

Amphetamines II qualitative assay results (AMP)

Roche ONLINE DAT AMPII assay	Low neg	Near cutoff negative by GC-MS (between -50 % and cutoff)	Near cutoff positive by GC-MS (between cutoff and +50 %)	High positive by GC-MS (greater than +50 %)	Percent agreement with GC-MS (total)
300 ng/mL cutoff					
Positive	0	3	4	36	100 %
Negative	36	1	0	0	92.5 %
500 ng/mL cutoff					
Positive	0	3	4	36	100 %
Negative	36	1	0	0	92.5 %
1000 ng/mL cutoff					
Positive	0	1	4	36	100 %
Negative	36	3	0	0	97.5 %

Amphetamines II semiquantitative assay results (AMP)

Roche ONLINE DAT AMPII assay	Low neg	Near cutoff negative by GC-MS (between -50 % and cutoff)	Near cutoff positive by GC-MS (between cutoff and +50 %)	High positive by GC-MS (greater than +50 %)	Percent agreement with GC-MS (total)
Positive	0	3	4	36	100 %
Negative	36	1	0	0	92.5 %

300 ng/mL cutoff					
Positive	0	3	4	36	100 %
Negative	36	1	0	0	92.5 %
500 ng/mL cutoff					
Positive	0	3	4	36	100 %
Negative	36	1	0	0	92.5 %
1000 ng/mL cutoff					
Positive	0	1	4	36	100 %
Negative	36	3	0	0	97.5 %

Accuracy samples were categorized based upon the *d*-amphetamine GC-MS concentration only. The table below identifies those samples with a *d*-amphetamine concentration below the cutoff, in which the observed result on a **cobas c 501** analyzer was positive. The expected results column identifies the result expected with the Amphetamines II assay based upon the *d*-amphetamine (AMP) value relative to the cutoff.

GC-MS summary of discrepant results (AMP)

Cutoff value (ng/mL)	Roche ONLINE DAT AMPII OBSERVED result	Roche ONLINE DAT AMPII EXPECTED result	GC-MS (ng/mL)	Drug / Metabolite
300 (SQ, Q)	Positive	Positive	157 363	AMP MAMP
300 (SQ, Q)	Positive	Positive	181 173	AMP MAMP
300 (SQ, Q)	Positive	Positive	220 171	AMP MAMP
500 (SQ, Q)	Positive	Positive	438 121	AMP MAMP
500 (SQ, Q)	Positive	Positive	457 1152	AMP MAMP
500 (SQ, Q)	Positive	Positive	443 706	AMP MAMP
1000 (SQ, Q)	Positive	Positive	837 1163	AMP MAMP

Additional clinical samples were evaluated with this assay on a **cobas c 503** analyzer and on a **cobas c 501** analyzer. 110 urine samples screened negative in a drug test panel, were evaluated with the Amphetamines II assay. 100 % of these normal urines were negative for all cutoffs relative to the **cobas c 503** analyzer. 55 urine samples for the 300 ng/mL and the 500 ng/mL cutoff and 53 urine samples for the 1000 ng/mL cutoff, screened preliminary positive with a commercially available immunoassay were evaluated with the Amphetamines II assay. At the 300 ng/mL cutoff, 55 urine samples and at the 500 ng/mL and 1000 ng/mL cutoffs, 51 urine samples were subsequently confirmed by GC-MS. At the 300 ng/mL, 500 ng/mL and 1000 ng/mL cutoffs, 100 % of the samples were positive on both the **cobas c 501** analyzer and the **cobas c 503** analyzer.

Amphetamines II correlation (cutoff = 300 ng/mL)

		cobas c 501 analyzer	
		+	-
cobas c 503 analyzer	+	55	0
	-	0	110

Amphetamines II correlation (cutoff = 500 ng/mL)

		cobas c 501 analyzer	
		+	-
Positive	0	3	4
Negative	36	1	0

cobas c 503 analyzer	+	55	0
	-	0	110

Amphetamines II correlation (cutoff = 1000 ng/mL)			
		cobas c 501 analyzer	
		+	-
cobas c 503 analyzer	+	53	0
	-	0	110

Additional clinical samples were evaluated with this assay on a **cobas c 303 analyzer** and on a **cobas c 501 analyzer**. Urine samples screened negative in a drug test panel, were evaluated with the Amphetamines II assay (112 samples negative relative to the 300 ng/mL cutoff, 110 samples negative relative to the 500 ng/mL cutoff and 112 samples negative relative to the 1000 ng/mL cutoff). 100 % of these normal urines were negative for the 300 ng/mL and the 500 ng/mL cutoffs on the **cobas c 303 analyzer**. For the 1000 ng/mL cutoff 99.1 % of these normal urines were negative on the **cobas c 303 analyzer**. Preliminary positive urine samples (53 samples relative to the 300 ng/mL, 55 samples relative to the 500 ng/mL cutoff and 50 samples relative to the 1000 ng/mL cutoff) were confirmed by GC-MS. For all cutoffs 100 % of these samples were positive on both the **cobas c 501 analyzer** and the **cobas c 303 analyzer**.

Amphetamines II correlation (cutoff = 300 ng/mL)			
		cobas c 501 analyzer	
		+	-
cobas c 303 analyzer	+	53	0
	-	0	112

Amphetamines II correlation (cutoff = 500 ng/mL)			
		cobas c 501 analyzer	
		+	-
cobas c 303 analyzer	+	55	0
	-	0	110

Amphetamines II correlation (cutoff = 1000 ng/mL)			
		cobas c 501 analyzer	
		+	-
cobas c 303 analyzer	+	50	1
	-	0	111

Additional clinical samples were evaluated with this assay on a **cobas c 703 analyzer** and on a **cobas c 503 analyzer**. Urine samples screened negative in a drug test panel, were evaluated with the Amphetamines II assay (110 samples negative relative to the 300 ng/mL cutoff, 113 samples negative relative to the 500 ng/mL cutoff and 125 samples negative relative to the 1000 ng/mL cutoff). 100 % of these normal urines were negative for the 300 ng/mL, the 500 ng/mL and the 1000 ng/mL cutoffs on the **cobas c 703 analyzer**. Preliminary positive urine samples (63 samples relative to the 300 ng/mL, 62 samples relative to the 500 ng/mL cutoff and 53 samples relative to the 1000 ng/mL cutoff) were confirmed by GC-MS. For all cutoffs 100 % of these samples were positive on both the **cobas c 503 analyzer** and the **cobas c 703 analyzer**.

Amphetamines II correlation (cutoff = 300 ng/mL)			
		cobas c 503 analyzer	
		+	-
cobas c 703 analyzer	+	63	0
	-	0	110

Amphetamines II correlation (cutoff = 500 ng/mL)			
		cobas c 503 analyzer	
		+	-
		+	-

cobas c 703 analyzer	+	62	0
	-	0	113

Amphetamines II correlation (cutoff = 1000 ng/mL)			
		cobas c 503 analyzer	
		+	-
cobas c 703 analyzer	+	53	0
	-	0	125

Analytical specificity

Serum/plasma

The specificity of Amphetamines II for various phenethylamines and structurally similar compounds was determined by generating inhibition curves for each of the compounds listed and determining the approximate quantity of each compound that is equivalent in assay reactivity to the 300 ng/mL *d*-methamphetamine assay cutoff. The following results were obtained on a **cobas c 501 analyzer**.

Compound	ng/mL Equivalent to 300 ng/mL <i>d</i> -methamphetamine	Approximate % cross-reactivity
<i>d</i> -Amphetamine	302	99.2
<i>d</i> -Methamphetamine	307	97.9
BDB ^{a)}	915	32.8
MBDB ^{b)}	357	84.1
MDA ^{c)}	248	121
MDEA ^{d)}	554	54.1
MDMA ^{e)}	196	153
<i>l</i> -Methamphetamine	5919	5.07
Phendimetrazine	38281	0.78
Phentermine	88086	0.34
Benfluorex	> 100000	n.d.
Tyramine	93000	0.32
Benzylamine	> 100000	n.d.
Chlorpheniramine	> 100000	n.d.
Chlorpromazine	> 100000	n.d.
Chloramphetamine	135	223
<i>l</i> -Ephedrine	118341	0.25
<i>d</i> -Pseudoephedrine	104227	0.29
<i>d,l</i> -Phenylpropanolamine	299838	0.10
<i>l</i> -Amphetamine	5932	5.06
<i>l</i> -Norpseudoephedrine	99822	0.30
Cathine	30763	0.98
<i>m</i> -CPP	3088	9.72
Labetalol	> 100000	n.d.
PMA ^{f)}	120	250
PMMA ^{g)}	126	238
1-Methyl-3-phenylpropylamine (APB) ^{h)}	1438	20.9

n.d. = not detectable

a) *d,l*-3,4-Methylenedioxyphenyl-2-butamine hydrochloride

b) *d,l*-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butamine hydrochloride

c) *d,l*-3,4-Methylenedioxyamphetamine

- d) d,l-3,4-Methylenedioxyethylamphetamine
 e) d,l-3,4-Methylenedioxymethamphetamine
 f) para-Methoxyamphetamine
 g) para-Methoxymethamphetamine
 h) APB, metabolite of Labetalol

Urine

The specificity of Amphetamines II for various phenethylamines and structurally similar compounds was determined by generating inhibition curves for each of the compounds listed for both semiquantitative and qualitative modes and determining the approximate quantity of each compound that is equivalent in assay reactivity to the 300 ng/mL, 500 ng/mL, and 1000 ng/mL *d*-methamphetamine assay cutoff. The tables below show the semiquantitative results of the study for each assay cutoff. The same samples were run in the qualitative mode and all recovered appropriately negative or positive, based on the calculated cross-reactivity. The following results were obtained on a Roche/Hitachi 917 analyzer.

Compound	ng/mL Equivalent to 300 ng/mL <i>d</i> -methamphetamine	Approx. % cross- reactivity
± MDMA ^{c)}	104	288
PMA ^{l)}	166	180
PMMA ^{m)}	191	157
± MDA ^{d)}	249	120
<i>d</i> -Amphetamine	251	120 ^{e)}
± MDEA ^{g)}	303	99
<i>d</i> -Methamphetamine	305	98
± MBDB HCl ^{f)}	323	93
± BDB HCl ^{h)}	717	42
Trazodone metabolite: mCPP ⁱ⁾	1631	18
1-Methyl-3-phenylpropylamine ^{j)}	1942	15
<i>l</i> -Methamphetamine	2524	12
<i>l</i> -Amphetamine	7085	4
Dimethylamylamine ^{k)}	30980	0.97
Phendimetrazine	31818	0.94
Phentermine	70391	0.43
<i>d</i> -Pseudoephedrine	73822	0.41
Tyramine	85115	0.35
Ranitidine	86997	0.34
<i>l</i> -Ephedrine	89655	0.33
<i>d,l</i> -Phenylpropanolamine HCl	211268	0.14
<i>d</i> -Ephedrine	215827	0.14

Compound	ng/mL Equivalent to 500 ng/mL <i>d</i> -methamphetamine	Approx. % cross- reactivity
± MDMA ^{c)}	196	255
PMA ^{l)}	341	147
PMMA ^{m)}	344	145
± MDA ^{d)}	394	127
<i>d</i> -Methamphetamine	488	102
<i>d</i> -Amphetamine	494	101 ^{e)}
± MBDB HCl ^{f)}	598	84
± MDEA ^{g)}	668	75
± BDB HCl ^{h)}	1358	37
Trazodone metabolite: mCPP ⁱ⁾	2560	20

1-Methyl-3-phenylpropylamine ^{j)}	2992	17
<i>l</i> -Methamphetamine	4383	11
<i>l</i> -Amphetamine	13342	4
Dimethylamylamine ^{k)}	50436	0.99
Phendimetrazine	65566	0.76
<i>d</i> -Pseudoephedrine	112613	0.44
Phentermine	123457	0.41
Ranitidine	127143	0.39
<i>l</i> -Ephedrine	141643	0.35
Tyramine	141643	0.35
<i>d,l</i> -Phenylpropanolamine HCl	344828	0.15
<i>d</i> -Ephedrine	458716	0.11

Compound	ng/mL Equivalent to 1000 ng/mL <i>d</i> -methamphetamine	Approx. % cross- reactivity
± MDMA ^{c)}	509	197
PMMA ^{m)}	690	145
PMA ^{l)}	908	110
± MDA ^{d)}	771	130
<i>d</i> -Amphetamine	981	102 ^{e)}
<i>d</i> -Methamphetamine	998	100
± MBDB HCl ^{f)}	1175	85
± MDEA ^{g)}	1553	64
± BDB HCl ^{h)}	2420	41
Trazodone metabolite: mCPP ⁱ⁾	5478	18
1-Methyl-3-phenylpropylamine ^{j)}	5116	20
<i>l</i> -Methamphetamine	8748	11
<i>l</i> -Amphetamine	24220	4
Dimethylamylamine ^{k)}	100735	0.99
Phendimetrazine	138504	0.72
Phentermine	238663	0.42
Ranitidine	257561	0.39
<i>d</i> -Pseudoephedrine	261780	0.38
Tyramine	284091	0.35
<i>l</i> -Ephedrine	308642	0.32
<i>d,l</i> -Phenylpropanolamine HCl	606061	0.17
<i>d</i> -Ephedrine	657895	0.15

c) d,l-3,4-Methylenedioxymethamphetamine

d) d,l-3,4-Methylenedioxyamphetamine

e) Representative data from multiple lots demonstrate cross-reactivity in the range from approximately 75-125 %

f) d,l-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butamine hydrochloride

g) d,l-3,4-Methylenedioxyethylamphetamine

h) d,l-3,4-Methylenedioxyphenyl-2-butamine hydrochloride

i) 1-(3-Chlorophenyl)piperazine

j) APB, metabolite of Labetalol

k) 4-Methylhexan-2-amine, DMAA

l) para-Methoxyamphetamine

m) para-Methoxymethamphetamine

Lisdexamfetamine is a pharmacologically inactive prodrug of *d*-amphetamine. After oral ingestion, lisdexamfetamine is converted to *l*-lysine and active *d*-amphetamine which may cause a positive test result with this assay.¹⁹

Drug interference*Serum/plasma*

Interfering substances were added to serum containing methamphetamine at -50 % and +50 % of the cutoff level at the concentrations listed below. Samples were tested and the following results were obtained on a **cobas c 501** analyzer.

Compound	Compd. conc. mg/L	Neg. level	Pos. level
Acetaminophen	200	neg	pos
Acetylcysteine	1660	neg	pos
Acetylsalicylic acid	1000	neg	pos
Amitriptyline	1.00	neg	pos
Ampicillin-Na	1000	neg	pos
Ascorbic acid	300	neg	pos
Caffeine	59.8	neg	pos
Cefoxitin	2500	neg	pos
Cyclosporine	5.00	neg	pos
Dextromethorphan	1.00	neg	pos
Doxycycline	50.0	neg	pos
Erythromycin	59.9	neg	pos
Fenoprofen	6.49	neg	pos
Furosemide	59.9	neg	pos
Gentisic acid	18.0	neg	pos
Heparin	5000 U/L	neg	pos
Hydrochlorothiazide	0.20	neg	pos
Ibuprofen	500	neg	pos
Ketamine	10.0	neg	pos
Levodopa	20.0	neg	pos
Lidocaine	12.0	neg	pos
LSD	2.50	neg	pos
Methyldopa + 1.5 H ₂ O	20.0	neg	pos
Metronidazole	200	neg	pos
Naproxen	499	neg	pos
Phenylbutazone	400	neg	pos
Procaine	2.00	neg	pos
Promethazine	1.20	neg	pos
Quinidine	12.0	neg	pos
Quinine	48.0	neg	pos
Rifampicin	60.0	neg	pos
Tetracycline	15.1	neg	pos
Theophylline	100	neg	pos
Trifluoperazine	1.00	neg	pos

*Urine***Cross-reactivity with unrelated drugs**

The following compounds were added at the listed concentrations to a human urine pool spiked with *D*-methamphetamine at approximately the negative and positive control concentrations for each cutoff (± 25 % of assay cutoff). For each compound, the control level samples recovered properly for the 300 ng/mL, 500 ng/mL, and 1000 ng/mL cutoff in both semiquantitative and qualitative modes.

**Semiquanti-
tative, all
cutoffs** **Qualitative,
all cutoffs**

Compound	Concentration (ng/mL)	Low control	High control	Low control	High control
Acetaminophen	100000	NEG	POS	NEG	POS
Acetylsalicylic acid	100000	NEG	POS	NEG	POS
Amitriptyline	100000	NEG	POS	NEG	POS
Ascorbic acid	100000	NEG	POS	NEG	POS
Aspartame	40000	NEG	POS	NEG	POS
Benzocaine	100000	NEG	POS	NEG	POS
Benzoyllecgonine	100000	NEG	POS	NEG	POS
Caffeine	100000	NEG	POS	NEG	POS
Cannabidiol	100000	NEG	POS	NEG	POS
Cocaine	100000	NEG	POS	NEG	POS
Codeine	100000	NEG	POS	NEG	POS
Desipramine HCl	100000	NEG	POS	NEG	POS
Dextromethorphan	100000	NEG	POS	NEG	POS
Dextropropoxyphene	100000	NEG	POS	NEG	POS
Diazepam	100000	NEG	POS	NEG	POS
Digoxin	100000	NEG	POS	NEG	POS
Diphenhydramine	100000	NEG	POS	NEG	POS
Diphenylhydantoin	100000	NEG	POS	NEG	POS
Doxepin	100000	NEG	POS	NEG	POS
Ecgonine	100000	NEG	POS	NEG	POS
Ecgonine methyl ester	100000	NEG	POS	NEG	POS
Erythromycin	100000	NEG	POS	NEG	POS
Furosemide	100000	NEG	POS	NEG	POS
Guaiacol glycerol ether	100000	NEG	POS	NEG	POS
Hydrochlorothiazide	100000	NEG	POS	NEG	POS
Ibuprofen	100000	NEG	POS	NEG	POS
Ketamine	100000	NEG	POS	NEG	POS
Levothyroxine	100000	NEG	POS	NEG	POS
LSD	2500	NEG	POS	NEG	POS
Meperidine	100000	NEG	POS	NEG	POS
Methadone	100000	NEG	POS	NEG	POS
Methaqualone	75000	NEG	POS	NEG	POS
Morphine	100000	NEG	POS	NEG	POS
Naloxone	100000	NEG	POS	NEG	POS
Naltrexone	100000	NEG	POS	NEG	POS
Naproxen	100000	NEG	POS	NEG	POS
Niacinamide	100000	NEG	POS	NEG	POS
Nicotine	100000	NEG	POS	NEG	POS
Nifedipine	100000	NEG	POS	NEG	POS
Nordiazepam	100000	NEG	POS	NEG	POS
Omeprazole	100000	NEG	POS	NEG	POS
Oxazepam	100000	NEG	POS	NEG	POS
Penicillin G	100000	NEG	POS	NEG	POS
Phencyclidine	40000	NEG	POS	NEG	POS
Phenobarbital	100000	NEG	POS	NEG	POS
Procaine	2500	NEG	POS	NEG	POS

Quinine	100000	NEG	POS	NEG	POS
Secobarbital	100000	NEG	POS	NEG	POS
Tetracycline	100000	NEG	POS	NEG	POS
Δ ⁹ -THC	10000	NEG	POS	NEG	POS

The compounds, including methylphenidate (Ritalin), were additionally added to aliquots of pooled drug-free human urine at a concentration of 100000 ng/mL. None of these compounds gave values in the assay that were equal to or greater than 0.17 % cross-reactivity and no results were greater than the assay cutoffs (300 ng/mL, 500 ng/mL, and 1000 ng/mL), with the following exceptions.

The compounds Labetalol HCl and Trazodone were additionally added to aliquots of pooled drug-free human urine at a concentration of 100000 ng/mL. The results obtained were between 0.21 % and 0.25 % for the 300 ng/mL, 500 ng/mL and the 1000 ng/mL assay cutoffs.

The cross-reactivity for LSD was tested at a concentration of 2500 ng/mL. The results obtained were 1.89 %, 1.76 %, and 1.43 %, for the 300 ng/mL, 500 ng/mL, and 1000 ng/mL assay cutoffs respectively.

The cross-reactivity for Δ⁹-THC-9-carboxylic acid was tested at a concentration of 10000 ng/mL. The results obtained were 0.56 %, 0.49 %, and 0.44 %, for the 300 ng/mL, 500 ng/mL, and 1000 ng/mL assay cutoffs respectively.

References

- Karch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.
- Borenstein M. Central Nervous System Stimulants. In: Troy D, ed. Remington: The Science and Practice of Pharmacy. 21st ed. Baltimore, MD: Lippincott Williams & Wilkins Co 2005;1551.
- Langman LJ, Bechtel LK, Holstege CP. Clinical Toxicology. In: Rifay N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, editors. Tietz Textbook of Laboratory Medicine, Saunders Elsevier, Philadelphia, 7th edition, 2023, chapter 43, p. 454-454.e84.
- NIDA Research Report - Methamphetamine Abuse and Addiction: NIH Publication No. 06-4210. National Institute on Drug Abuse 6001 Executive Blvd. Room 5213, Bethesda, MD 20892-9561. Available from: <https://nida.nih.gov/sites/default/files/methrrs.pdf>
- SCDAT - Swiss Guidelines Committee for Drugs of Abuse Testing. Guidelines for Drugs of Abuse Testing. Vers EN 2021-03-25 (corrected 2022-12-6). Available from: https://www.scdat.ch/documents/SCDAT_Guidelines_EN_2021_03_25_corr20221206.pdf
- Jannetto PJ, Bratanow NC, Clark WA, et al. Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. J Appl Lab Med 2018 Jan 1;2(4):489-526.
- Jarvis M, Williams J, Hurford M, et al. Appropriate Use of Drug Testing in Clinical Addiction Medicine. J Addict Med 2017 May/Jun;11(3):163-173.
- Substance Abuse and Mental Health Services Administration. Clinical Drug Testing in Primary Care. Technical Assistance Publication (TAP) 32. HHS Publication No. (SMA) 12-4668. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2012. Available from: <https://store.samhsa.gov/sites/default/files/d7/priv/sma12-4668.pdf>
- Taskinen S, Beck O, Bosch T, et al. European guidelines for workplace drug testing in urine. Drug Test Anal 2017 Jun;9(6):853-865.
- Brahm NC, Yeager LL, Fox MD, et al. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm 2010 Aug 15;67(16):1344-1350.
- Armbruster DA, Schwarzhoff RH, Pierce BL, et al. Method comparison of EMIT II and ONLINE with RIA for drug screening. J Forensic Sci 1993;38:1326-1341.
- Armbruster DA, Schwarzhoff RH, Hubster EC, et al. Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drugs-of-abuse screening. Clin Chem 1993;39:2137-2146.
- Rouse S, Motter K, McNally A, et al. An Abuscreen OnLine Immunoassay for the Detection of Amphetamine in Urine on the COBAS MIRA Automated Analyzer. Clin Chem 1991;37(6):995. Abstract.
- Toxicology and Drug Testing in the Clinical Laboratory; Approved Guideline. 2nd ed. (C52-A2). Clinical and Laboratory Standards Institute 2007;27:33.
- Mandatory Guidelines for Federal Workplace Drug Testing Programs. Fed Regist 2017 Jan 23;82:7920-7970.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- Peters FT, Kraemer T, Maurer HH. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. Clin Chem 2002;48(9):1472-1485.
- Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: A single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008;48(3):293-302.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard:

CONTENT

Contents of kit



Volume for reconstitution

GTIN

Global Trade Item Number

Rx only

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

ABUSCREEN, COBAS, NAVIFY, ONLINE DAT and PRECISET are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2024, Roche Diagnostics

CE 0123

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany
www.roche.com

+800 5505 6606

